|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
10/16/2012 8:41:08 AM
The Kalamazoo-based medical device maker announced Oct. 16 it is purchasing Surpass Medical, Ltd., for $135 million. Stryker will pay $100 million in cash for the privately held company, with up to $35 million in additional milestone payments. Surpass, which was founded in 2005 and based in Tel Aviv, Israel, with manufacturing and research and development in Miramar, Fla., is developing a next-generation stent technology using a mesh design and delivery system to divert blood flow. The NeuroEndGraft family of flow diverters is designed to redirect blood flow away from an aneurysm, allowing a stable clot of be formed. "The acquisition of Surpass Medical further builds on Stryker's global platform in the fast growing and highly innovative neurovascular market and helps broaden our offering in complete stroke care," said Kevin A. Lobo, president and chief executive officer, in a statement. "We remain committed to furthering care in the interventional neurovascular space by offering patients and caregivers differentiated products that improve outcomes and help save lives."
|
|
|
|
|
|
|
|
|
|
|